As opposed to previous speculations over DPP-4 inhibitors’ potential link to pneumonia risks, the current study findings indicate that DPP-4 inhibitors pose no detrimental effects on respiratory tract infections, but rather exert protective effects especially in male patients with progressed T2DM already on insulin therapy. The gene discussed is INS; the disease is pneumonia.